<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00572897</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 07-0548-00101</org_study_id>
    <secondary_id>P01CA108671-01A2</secondary_id>
    <secondary_id>MPD-RC 101</secondary_id>
    <nct_id>NCT00572897</nct_id>
  </id_info>
  <brief_title>Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis</brief_title>
  <official_title>Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Mascarenhas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Myeloproliferative Disorders-Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stem cell transplantation is used to treat may types of diseases. There a 2 types of
      transplants, conventional (very intense) and reduced intensity-non-myeloablative, also called
      mini-transplants.

      This study proposes to use a conditioning regimen for allogeneic transplantation along with a
      reduced intensity transplant. Conditioning regiment is the name for the combination of
      chemotherapy drugs that is given to patients before receiving a transplantation of donor stem
      cells. It is hoped that the regimen designed for this study proves to be less toxic and has
      an equal or better anticancer effect than the regimens that are normally used. The regimen
      being used is a combination of two chemotherapy drugs, fludarabine and melphalan. This
      regimen has been studied in recipients of matched sibling transplants and in recipients of
      alternative donor stem cells in other hematologic malignancies. Those subjects, who receive
      stem cells from an unrelated donor, will also receive and additional drug called ATG or anti
      thymocyte globulin. ATG suppresses the immune system, thus reducing the chances for the
      recipient rejecting the transplant (graft).

      The purpose of this study is to observe if reduced intensity transplants can be used to allow
      engraftment or &quot;take&quot; of the donor's bone marrow. Studies conducted in the past show this
      type of transplant is much less toxic than traditional bone marrow transplants. Reduced
      intensity transplants may be better tolerated by patients who may experience serious side
      effects from standard (very intense) stem cell transplant.

      The study has been recently amended to follow all subjects for survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a single arm Phase II clinical trial in patients with myelofibrosis
      who are eligible for transplantation from a related donor or from an unrelated donor source.
      Patients will be accrued into two separate strata defined by donor type. Each of the two
      strata will be analyzed separately.

      Patients will be followed yearly from time of enrollment into the study to assess clinical
      response and overall, progression and event free survival, as well as incidence and degree of
      acute and chronic GVHD. We will estimate cumulative survival and transplant related mortality
      in patients enrolled in each of the two strata.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">June 15, 2015</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Endpoint is Progression-free Survival.</measure>
    <time_frame>2 years</time_frame>
    <description>Number of participants alive at 2 years who are progression-free</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Outcomes</measure>
    <time_frame>180 days</time_frame>
    <description>assessed according to the IWG Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>73 months</time_frame>
    <description>The number of patients alive at last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Neutrophil Count (ANC)</measure>
    <time_frame>2 years</time_frame>
    <description>Patients with ANC ≥0.5 × 10^9/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PLT</measure>
    <time_frame>2 years</time_frame>
    <description>Patients with PLT ≥20 × 109/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related Mortality</measure>
    <time_frame>2 years</time_frame>
    <description>Transplant-related Mortality including Graft-versus-host disease (GVHD)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Fludarabine, Melphalan +/- ATG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine, Melphalan +/- ATG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine, Melphalan +/- ATG</intervention_name>
    <description>Conditioning regimen for Allogenic Stem Cell Transplant:
Related Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily)
Unrelated Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily) ATG (Thymoglobulin®) days -3 to -1 (0.5 mg/kg IV on day -3 [given over 6 hours], and 2 mg/kg on days -2 and -1 [given over 4 hours])</description>
    <arm_group_label>Fludarabine, Melphalan +/- ATG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the following disease: Idiopathic myelofibrosis, or spent PV-, or
             ET-related myelofibrosis in chronic phase (&lt;20% blast cells in the bone marrow) with
             Lille score &gt;1 at any time, or platelet &lt;100K.

          -  Age 18-65 years.

          -  ECOG performance status &lt; 3.

          -  Life expectancy &gt;3 months.

          -  Adequate cardiac function, normal LVEF ≥ 45% by MUGA or echocardiogram and adequate
             pulmonary function DLCO ≥ 50% of predicted.

          -  Serum creatinine &lt; 1.1 x the upper limit of normal (ULN) or Creatinine Clearance &gt;50
             ml/min.

          -  Serum bilirubin &lt; 2.0 mg/dl, SGPT &lt;2.5 x upper limit of normal

          -  No evidence of chronic active hepatitis or cirrhosis

          -  HIV-negative

          -  Patient is not pregnant

          -  Patient or guardian able to sign informed consent.

          -  Patients with &gt;20% myeloblasts in the blood or marrow, extramedullary blast cell
             proliferation or large foci of blasts in bone marrow biopsy specimens are not
             eligible.

          -  Pretransplant splenectomy: MMM patients with variable degrees of splenomegaly, or
             splenectomized, are eligible to be enrolled. Any decision of having a patient
             splenectomized prior to transplant will be made in each center prior to enrolling the
             patient in the study.

          -  Patients should be off treatment with investigational for at least 4 weeks and have
             recovered from all toxicities.

        Exclusion Criteria:

          -  Pregnancy

          -  HIV positive

          -  &gt; 20% myeloblasts in the peripheral blood or bone marrow

          -  LVEF &lt; 45%

          -  DLCO &lt; 50% of predicted

          -  ECOG performance status ≥ 3

          -  Chronic active hepatitis or cirrhosis

          -  Chronic renal insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Mascarenhas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Giovanni Barosi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Myeloproliferative Disorders-Research Consortium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Damiano Rondelli, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Myeloproliferative Disorders-Research Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State Univesity</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florence</name>
      <address>
        <city>Florence</city>
        <state>IL</state>
        <zip>60302</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of San Martino</name>
      <address>
        <city>San Martino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionala etikprovningsnamnden Goteborg</name>
      <address>
        <city>Goteborg</city>
        <zip>60302</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Italy</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Rondelli D, Goldberg JD, Isola L, Price LS, Shore TB, Boyer M, Bacigalupo A, Rambaldi A, Scarano M, Klisovic RB, Gupta V, Andreasson B, Mascarenhas J, Wetzler M, Vannucchi AM, Prchal JT, Najfeld V, Orazi A, Weinberg RS, Miller C, Barosi G, Silverman LR, Prosperini G, Marchioli R, Hoffman R. MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis. Blood. 2014 Aug 14;124(7):1183-91. doi: 10.1182/blood-2014-04-572545. Epub 2014 Jun 24.</citation>
    <PMID>24963042</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 11, 2007</study_first_submitted>
  <study_first_submitted_qc>December 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2007</study_first_posted>
  <results_first_submitted>November 21, 2014</results_first_submitted>
  <results_first_submitted_qc>April 21, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 2, 2016</results_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>John Mascarenhas</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Myelofibrosis</keyword>
  <keyword>Myeloproliferative disease</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>Allogeneic Transplant</keyword>
  <keyword>Conditioning Regimen</keyword>
  <keyword>Reduced Intensity Regimen</keyword>
  <keyword>Fludarabine</keyword>
  <keyword>Melphalan</keyword>
  <keyword>ATG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from 2007 to 2011 at 11 centers affiliated with the Myeloproliferative Disorders Research Consortium (MPD-RC)</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sibling Donor</title>
          <description>Patients received a stem cell transplant from sibling</description>
        </group>
        <group group_id="P2">
          <title>Unrelated Donor</title>
          <description>Patients received a stem cell transplant from an unrelated donor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients with myelofibrosis who received a stem cell transplant from either a sibling or unrelated donor.</population>
      <group_list>
        <group group_id="B1">
          <title>Sibling Donor</title>
          <description>Patients received a stem cell transplant from sibling</description>
        </group>
        <group group_id="B2">
          <title>Unrelated Donor</title>
          <description>Patients received a stem cell transplant from an unrelated donor</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="66"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Median age at the time of transplant</description>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" lower_limit="40" upper_limit="65"/>
                    <measurement group_id="B2" value="56" lower_limit="30" upper_limit="65"/>
                    <measurement group_id="B3" value="55" lower_limit="30" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <description>Primary Myelofibrosis (PMF); Post-Polycythemia vera (PV-MF); Post-Essential Thrombocythemia (ET-MF)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>PMF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PV-MF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ET-MF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lille score</title>
          <description>The Lille scoring system was created by Dupriez and coworkers and used in selecting intermediate- and higher-risk patients as candidates for Autologous Stem Cell Transplant (ASCT). A platelet count of &gt;100 × 109/L in patients with IM was associated with an adverse outcome and created a complete blood count scoring system using three parameters: Hgb &lt; 10 gm/dL; WBC &lt; 4 or &gt; 30 × 109/L; and platelet count &lt;100 × 109/L. Each event was given a score of 1. Higher scores indicate lower median survival.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patient: donor gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female:Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male:Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male:Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female:Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>JAK-2V617F</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bone Marrow Fibrosis</title>
          <description>European consensus on grading bone marrow fibrosis:
MF - 0 Scattered linear reticulin with no intersections (cross-overs) corresponding to normal bone marrow; MF - 1 Loose network of reticulin with many intersections, especially in perivascular areas; MF - 2 Diffuse and dense increase in reticulin with extensive intersections,occasionally with only focal bundles of collagen and/or focal osteosclerosis; MF - 3 Diffuse and dense increase in reticulin with extensive intersections with coarse bundles of collagen, often associated with significant osteosclerosis</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Splenomegaly</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Splenectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Karyotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>One abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complex abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stem cell source</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Peripheral blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone Marrow</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HLA match</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Full HLA matched</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HLA 1 Ag mismatched, no allele mismatched</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HLA Ag matched, 1 0r 2 alleles mismatched</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Endpoint is Progression-free Survival.</title>
        <description>Number of participants alive at 2 years who are progression-free</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sibling Donor</title>
            <description>Patients received a stem cell transplant from sibling</description>
          </group>
          <group group_id="O2">
            <title>Unrelated Donor</title>
            <description>Patients received a stem cell transplant from an unrelated donor</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Endpoint is Progression-free Survival.</title>
          <description>Number of participants alive at 2 years who are progression-free</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Outcomes</title>
        <description>assessed according to the IWG Criteria</description>
        <time_frame>180 days</time_frame>
        <population>Clinical responses were assessed according to the IWG-MRT 2006 criteria in 46 patients (29 sibling and 17 unrelated transplants) who survived at least 180 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Sibling Donor</title>
            <description>Patients received a stem cell transplant from sibling</description>
          </group>
          <group group_id="O2">
            <title>Unrelated Donor</title>
            <description>Patients received a stem cell transplant from an unrelated donor</description>
          </group>
        </group_list>
        <measure>
          <title>Response Outcomes</title>
          <description>assessed according to the IWG Criteria</description>
          <population>Clinical responses were assessed according to the IWG-MRT 2006 criteria in 46 patients (29 sibling and 17 unrelated transplants) who survived at least 180 days.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>clinical complete response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>clinical partial response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>clinical improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>stable disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>progressive disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The number of patients alive at last follow-up.</description>
        <time_frame>73 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sibling Donor</title>
            <description>Patients received a stem cell transplant from sibling</description>
          </group>
          <group group_id="O2">
            <title>Unrelated Donor</title>
            <description>Patients received a stem cell transplant from an unrelated donor</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The number of patients alive at last follow-up.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Neutrophil Count (ANC)</title>
        <description>Patients with ANC ≥0.5 × 10^9/L</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sibling Donor</title>
            <description>Patients received a stem cell transplant from sibling</description>
          </group>
          <group group_id="O2">
            <title>Unrelated Donor</title>
            <description>Patients received a stem cell transplant from an unrelated donor</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Neutrophil Count (ANC)</title>
          <description>Patients with ANC ≥0.5 × 10^9/L</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PLT</title>
        <description>Patients with PLT ≥20 × 109/L</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sibling Donor</title>
            <description>Patients received a stem cell transplant from sibling</description>
          </group>
          <group group_id="O2">
            <title>Unrelated Donor</title>
            <description>Patients received a stem cell transplant from an unrelated donor</description>
          </group>
        </group_list>
        <measure>
          <title>PLT</title>
          <description>Patients with PLT ≥20 × 109/L</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transplant-related Mortality</title>
        <description>Transplant-related Mortality including Graft-versus-host disease (GVHD)</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sibling Donor</title>
            <description>Patients received a stem cell transplant from sibling</description>
          </group>
          <group group_id="O2">
            <title>Unrelated Donor</title>
            <description>Patients received a stem cell transplant from an unrelated donor</description>
          </group>
        </group_list>
        <measure>
          <title>Transplant-related Mortality</title>
          <description>Transplant-related Mortality including Graft-versus-host disease (GVHD)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>all adverse events reported under serious adverse events. other non-serious adverse events were not separated out.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sibling Donor</title>
          <description>Patients received a stem cell transplant from sibling</description>
        </group>
        <group group_id="E2">
          <title>Unrelated Donor</title>
          <description>Patients received a stem cell transplant from an unrelated donor</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Progression of disease</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>hemorrhage</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Heart Failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>acute graft-versus-host disease (aGVHD)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Viral infection</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Secondary malignancy</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Renal Failure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Respiratory failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Transplant-related complications</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="34"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Event secondary to graft failure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Venous occlusive disease</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Damiano Rondelli</name_or_title>
      <organization>Univeristy of Illinois Hospital &amp; Health Sciences System</organization>
      <phone>312-996-6179</phone>
      <email>drond@uic.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

